

FireGate Biotech Inc.
FOR IMMEDIATE RELEASE

FireGate Biotech Announces Launch and Early Research Programs Focused on Immune Modulation

Update highlights early development across FG-001 (HIV), FG-002 (oncology viral mimicry), and FG-003 (neuro-immune repair)

Washington, DC — November 2025 — FireGate Biotech Inc., a research-focused biotechnology company developing modular immune-directed research programs, today announced its public launch and outlined early scientific initiatives exploring coordinated immune signaling mechanisms across infectious disease, oncology, and neuro-immune biology.

FireGate’s research strategy focuses on triplet-directed immunologic modulation, investigating interactions between immune checkpoint signaling, receptor-mediated trafficking pathways, and antibody-directed immune recruitment mechanisms. These programs aim to explore how coordinated immune pathways may influence disease biology across multiple therapeutic areas.

FireGate also acknowledges the broader scientific dialogue surrounding immune modulation research, including public discussions referencing related concepts by **Dr. Sajad Sarvari** and **Dr. Faezeh Moakedi**. These discussions reflect growing scientific interest in immune-directed therapeutic approaches.

Throughout 2025, FireGate began establishing foundational infrastructure supporting scientific collaboration and early translational planning. Initial research datasets have been released through the Harvard Dataverse, and the company continues engaging academic collaborators and research organizations aligned with its developing research programs.

FireGate Research Pipeline

- **FG-001 — HIV:** Exploration of immune-directed strategies addressing viral persistence and immune exhaustion mechanisms associated with HIV infection.
- **FG-002 — Oncology:** Investigation of viral mimicry and endogenous retroviral signaling pathways that may enhance tumor immunogenicity and immune recognition.
- **FG-003 — Neuro-Immune Repair:** Research focused on microglial regulation, neuro-inflammatory signaling, and mechanisms associated with remyelination and central nervous system repair.

In addition to foundational research planning, FireGate has produced educational materials and scientific summaries describing the conceptual frameworks underlying these programs.

Media Coverage

FireGate Biotech’s public launch announcement was also reported by BioSpace:

BioSpace — FireGate Biotech Announces Launch and Early Research Programs Focused on Immune Modulation

Research Status

The research initiatives described in this announcement are exploratory and represent early-stage scientific investigations. Further validation and development will be required to evaluate potential translational applications.

About FireGate Biotech Inc.

FireGate Biotech Inc. is a veteran-founded biotechnology company exploring modular immune-directed strategies across infectious disease, oncology, and neuro-immune biology. The company's research pipeline includes three programs — FG-001, FG-002, and FG-003 — investigating coordinated immune signaling mechanisms that may support future therapeutic discovery.

Media Contact

FireGate Biotech Inc.
Washington, DC, USA
<https://firegatebiotech.com>